Tara Biosystems, Inc., a NYC-based provider of physiologically-relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, raised $2.25m in seed funding.
The round was led by Harris & Harris Group with participation from the Partnership Fund for New York City and Alexandria Venture Investments.
The company intends to use the funds to build commercial operations in New York City.
Based on research from the laboratories of Columbia University Professor Gordana Vunjak-Novakovic and University of Toronto Professor Milica Radisic, both scientific co-founders, Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery and safety assessment. The company’s cardiac tissues are produced from human induced pluripotent stem cell-derived cardiomyocytes, matured to an adult-like phenotype, and interrogated to provide direct measures of cardiac functionality, including contractile force.